-

Shareholder Alert: Robbins LLP Announces that Aurora Cannabis, Inc. (ACB) is Being Sued for Misleading Shareholders

SAN DIEGO & EDMONTON, Alberta--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a purchaser of Aurora Cannabis, Inc. (NYSE: ACB) has filed a class action complaint against the company's officers for alleged violations of the Securities Exchange Act of 1934 between February 13, 2020 and September 4, 2020. Based in Edmonton, Canada, Aurora produces and distributes medical cannabis products worldwide.

If you suffered a loss due to Aurora Cannabis, Inc.'s misconduct, click here.

Aurora Cannabis, Inc. (ACB) Accused of Failing to Disclose Sizable Impairment Charges

According to the complaint, during the relevant period, Aurora Cannabis, Inc. failed to disclose that it had significantly overpaid for recently acquired assets while the value of others depreciated. When Canada passed the Cannabis Act in 2018 and reshaped the marijuana industry, Aurora completed a series of acquisitions intended to strengthen its position in the marketplace, including the purchase of MedReleaf, a medical cannabis producer, for 3.2 billion Canadian dollars. Aurora encountered issues such as regulatory delays, overproduction, and black market competition. On February 6, 2020, Aurora issued a press release detailing its business transformation plan, aimed at better aligning the company with the "current realities of the cannabis market." However, the plan was inadequate in addressing the company's situation. The plan's shortfall was even further evident after Aurora's September 8, 2020 press release, which revealed that the company expected to record $1.8 billion in goodwill charges in 2020's fourth quarter, including up to $90 million in fixed asset impairment charges, and $140 million to carry the value of certain inventory. On this news, Aurora stock price fell 11.63% to close at $7.52 per share on September 8, 2020.

If you purchased Aurora Cannabis, Inc. (ACB) securities between February 13, 2020 and September 4, 2020, you have until December 1, 2020, to ask the court to appoint you lead plaintiff for the class.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against Aurora Cannabis, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Did You Lose Money in Stride, Inc.? Contact Robbins LLP for Information About Your Rights Against LRN.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: The company: Stride, Inc. (NYSE: LRN) is a technology company that provides an education platform to deliver online learning to students throughout the U.S. What is the class period? October 22, 2024 - October 28, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Stride during the class period because the Company allegedly misled investors regarding i...

Did You Lose Money in Perrigo Company? PRGO Stockholders Should Contact Robbins LLP for Information About Their Rights Against PRGO.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Perrigo Company (NYSE: PRGO) provides over-the-counter health and wellness solutions in the U.S., Europe, and internationally. What is the class period? February 27, 2024 - November 4, 2025 What is the Case About? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who acquired Perrigo securities during the class period because the Company allegedly misled investors regarding the value of its infant formula...

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Skye Bioscience, Inc. (NYSE: SKYE) is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors (“GPCRs”) to treat obesity, overweight, and metabolic diseases. The Company’s lead product candidate is nimacimab. What is the class period? November 4, 2024 - October 3, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors...
Back to Newsroom